Overview

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects

Status:
Completed

Trial end date:
2010-07-15

Target enrollment:

Participant gender:

Summary

This study is being done to look at the absolute bioavailability of fluticasone furoate and GW642444 inhalation powder when administered in healthy subjects. Bioavailability is determined by measuring the amount of the dose of inhaled medication that reaches the circulation; the amount of inhaled fluticasone furoate and GW642444 powder will be compared to the medication administered intravenously (where bioavailability is 100%).

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Fluticasone
Xhance